NYSE:BSX

Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$43.06 -0.63 (-1.45%)
Closing price 03:59 PM Eastern
Extended Trading
$42.98 -0.07 (-0.16%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Boston Scientific Stock (NYSE:BSX)

Advanced

Key Stats

Today's Range
$43.02
▼
$43.83
50-Day Range
$41.55
▼
$46.03
52-Week Range
$39.57
▼
$101.91
Volume
12.90 million shs
Average Volume
18.69 million shs
Market Capitalization
$62.41 billion
P/E Ratio
18.24
Dividend Yield
N/A
Price Target
$61.43
Consensus Rating
Moderate Buy

Company Overview

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts.

Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Boston Scientific serves healthcare providers and patients around the world. Its portfolio is organized around cardiovascular and MedSurg businesses, reflecting the range of specialties and procedures its products support.

AI Generated. May Contain Errors.

Boston Scientific Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

BSX MarketRank™: 
4.174628450105 of 5 stars

Boston Scientific scored higher than 83% of companies evaluated by MarketBeat, and ranked 57th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 20 buy ratings, 8 hold ratings, and 2 sell ratings.

  • Upside Potential

    Boston Scientific has a consensus price target of $61.43, representing about 42.7% upside from its current price of $43.06.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to decrease by -2.52% in the coming year, from $3.17 to $3.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 18.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.92.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 18.24, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.17.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 1.31. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    2.43% of the float of Boston Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 1.65, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently decreased by 13.74%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • News Sentiment

    Boston Scientific has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Boston Scientific this week, compared to 8 articles on an average week.
  • Search Interest

    Only 56 people have searched for BSX on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.
  • MarketBeat Follows

    17 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 89% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    0.34% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Stock News Headlines

The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
Boston Scientific: A Longer Road To Recovery (Rating Downgrade)
RxSight (NASDAQ:RXST) vs. Boston Scientific (NYSE:BSX) Financial Comparison
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $95.29 at the beginning of 2026. Since then, BSX stock has decreased by 54.8% and is now trading at $43.0560.

Boston Scientific Corporation (NYSE:BSX) issued its earnings results on Wednesday, October, 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.73 by $0.00. The company's revenue for the quarter was up 1.4% on a year-over-year basis.
Read the conference call transcript
.

Boston Scientific's Board of Directors authorized a stock repurchase plan on Monday, May 18th 2026, which permits the company to buy back $5 billion in outstanding shares, according to EventVestor. This means that the company could purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's board of directors believes its shares are undervalued.

The following companies are subsidiaries of Boston Scientific: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and others.

Top institutional investors of Boston Scientific include State Street Corp (4.64%), Dodge & Cox (1.03%), Assenagon Asset Management S.A. (0.47%) and Toronto Dominion Bank (0.28%). Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Eric Francis Yves Thepaut, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jeffrey B Mirviss, Ellen M Zane, Arthur C Butcher, John Bradley Sorenson, David C Habiger, Yoshiaki Fujimori, Cheryl Pegus and Charles J Dockendorff.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Intel (INTC), Micron Technology (MU), Tesla (TSLA), Salesforce (CRM) and Visa (V).

Company Calendar

Last Earnings
10/28/2026
Today
11/17/2026
Fiscal Year End
12/31/2026
Next Earnings (Estimated)
2/03/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:BSX
CIK
885725
Employees
59,000
Year Founded
1979

Price Target and Rating

High Price Target
$118.00
Low Price Target
$44.00
Potential Upside/Downside
+42.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
31 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.36
Trailing P/E Ratio
18.24
Forward P/E Ratio
13.93
P/E Growth
1.31
Net Income
$2.90 billion
Net Margins
16.62%
Pretax Margin
17.35%
Return on Equity
18.61%
Return on Assets
10.58%

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
1.36
Quick Ratio
0.81

Sales & Book Value

Annual Sales
$21.07 billion
Price / Sales
2.96
Cash Flow
$3.93 per share
Price / Cash Flow
10.95
Book Value
$17.85 per share
Price / Book
2.41

Miscellaneous

Outstanding Shares
1,449,473,000
Free Float
1,444,545,000
Market Cap
$62.41 billion
Optionable
Optionable
Beta
0.60

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NYSE:BSX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners